iShares Biotechnology ETF (NQ:IBB)

IBB has delivered stronger returns than IYH but with dramatically sharper swings in both directions. Here is how to decide which trade-off fits your portfolio.

Topics ETFs

Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? ↗

October 11, 2026

Better Healthcare ETF: Vanguard's Broad VHT vs. the iShares Biotechnology-Focused IBB ↗

Topics ETFs

October 05, 2026

VHT offers broad sector exposure, while IBB concentrates on biotech with higher growth but steeper drawdowns.

iShares offers lower fees and concentrated biotech exposure with stronger 1-year returns, while Simplify provides broader healthcare diversification and a higher dividend yield.

Topics ETFs

Better Healthcare ETF: iShares Biotechnology-Focused IBB vs. Simplify's Broad PINK ↗

September 25, 2026

XLV offers exposure to the broader healthcare sector, while IBB targets biotech innovators. Here's how the two stack up on risk, returns, and diversification.

Topics ETFs

XLV vs IBB: How Healthcare Diversification Compares to Biotech Concentration ↗

September 24, 2026

Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.

Topics ETFs

2 Biotech Stocks Shaping Up for Major Breakouts ↗

August 22, 2026

Which iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB? ↗

Topics ETFs

July 23, 2026

IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the volatility and a 1.5% dividend yield.

First Trust's 30-stock strategy delivered 53.2% returns over one year, but comes with higher concentration risk and a steeper 11-basis-point fee.

Topics ETFs

Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance? ↗

July 12, 2026

Established pharmaceutical giants have delivered lower volatility and higher income than clinical-stage biotech exposure over the past five years.

Topics ETFs

IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy? ↗

July 10, 2026

Broad healthcare diversification or concentrated biotech growth? Compare cost, risk, and portfolio composition to find your fit.

Topics ETFs

Vanguard Health Care vs. iShares Biotech: How Do These ETFs Stack Up? ↗

July 04, 2026

Compare portfolio diversity, risk profiles, and income potential as you weigh these two leading healthcare ETFs.

Topics ETFs

SPDR Health Care ETF Tops iShares Biotech in Long-Term Returns ↗

July 02, 2026

As AI stocks face volatility, capital is rotating into biotech, industrials, utilities, consumer staples, and dividend ETFs showing relative strength.

Topics ETFs

5 Places Investors Can Hide If the AI Trade Keeps Cracking ↗

June 29, 2026

SpaceX IPO buzz faded as AI volatility, hotter inflation, and a shortened trading week shifted investor focus toward earnings season

Topics Artificial Intelligence ETFs

MarketBeat Week in Review – 06/22 - 06/26 ↗

June 27, 2026

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

Topics Artificial Intelligence Economy Initial Public Offering

The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. ↗

June 23, 2026

With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.

Topics ETFs

2 Ways to Play the Big Pharma Patent Cliff ↗

May 15, 2026

In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF...

Topics ETFs Intellectual Property

Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally

March 31, 2026

Via MarketMinute

Topics ETFs Intellectual Property Stocks

DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗

March 21, 2026

iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but...

QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure ↗

Topics Derivatives ETFs Regulatory Compliance

March 10, 2026

H.C. Wainwright stated that the reported departure of a key U.S. Food and Drug Administration official at the end of April bodes well for uniQure.

QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 ↗

Topics Initial Public Offering

March 09, 2026

Wells Fargo upgraded uniQure’s stock to ‘Overweight,’ citing a bullish outlook for its gene therapy following reports that Vinay Prasad will leave the U.S. FDA next month.

The company reported mixed Q4 results with a revenue of $128.6 million and earnings per share of $0.16.

Why Did CRMD Stock Tumble Over 11% Today? ↗

March 05, 2026

BioXcel announced positive Phase 2 results for evaluating treatment for opioid withdrawal symptoms.

Topics Artificial Intelligence

Why Did BTAI Stock Surge 20% In Pre-Market Today? ↗

March 05, 2026

The company tied up with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA using a proprietary ECO Synthesis platform.

Why Did CDXS Stock Jump 7% Today? ↗

March 04, 2026

AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial ↗

March 02, 2026

Aardvark Therapeutics shares saw brokerage downgrades after the company paused its Phase 3 trial to treat hyperphagia in patients with Prader-Willi syndrome.

Aurinia reported adjusted earnings per share of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.

AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates ↗

February 26, 2026

VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership ↗

February 24, 2026

Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12.

ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 1% Pre-Market ↗

February 23, 2026

Net product revenue in the fourth quarter surged 431% to $38.3 million, above estimates of $37.8 million, according to Fiscal.ai data

Gilead Sciences announced an agreement to acquire Arcellx in a $7.8 billion deal.

Why Did ACLX Stock Surge 80% In Pre-Market Today? ↗

February 23, 2026

SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition ↗

February 18, 2026

The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio.

CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial ↗

February 17, 2026

COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

CMPS Stock Jumps 22% Pre-Market As Compass Sets Timeline For New Phase 3 Depression Trial Results ↗

February 17, 2026

The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.